Japanese Team To Try Stem Cells To Fix Premature Infant Disease
This article was originally published in PharmAsia News
A biomedical engineering team in Japan plans to test transplanting stem cells in newborns to regenerate lost nerve cells behind a type of encephalopathy. The brain disease PVL occurs in about 10 percent of infants delivered by 33 weeks of pregnancy. The Nagoya City University team plans to experiment on animals by using pluropotent stem cells from mice and monkeys to generate neural stem cells that would be transplanted back into the days-old animal engineered to develop PVL symptoms. (Click here for more
You may also be interested in...
Procter & Gamble, through its UK wellness subsidiary Nature's Best, is on-trend with new vegan vitamin D3 and iron supplements. Nature's Best has also launched three other vitamin D3 products in the country, as well as an ashwagandha supplement.
The MHRA has updated its guidance on regulatory flexibilities for medical devices and medicinal products resulting from COVID-19 to highlight how its approach differs from the EU.
The Swiss company is planning a US trial of CBSO, the first transcatheter septal occluder with a bioresorbable, metal-free frame.